{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:02:42Z","timestamp":1791478962700,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1614,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1177\/0091270010370846","type":"journal-article","created":{"date-parts":[[2010,5,21]],"date-time":"2010-05-21T02:24:47Z","timestamp":1274408687000},"page":"575-585","source":"Crossref","is-referenced-by-count":28,"title":["Effects of Commonly Administered Agents and Genetics on Nebivolol Pharmacokinetics: Drug-Drug Interaction Studies"],"prefix":"10.1002","volume":"51","author":[{"given":"Charles","family":"Lindamood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ","family":"Rackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Christopher","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"issue":"suppl 2","key":"10.1177\/0091270010370846-BIB1|cit1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2036.2007.03490.x","article-title":"Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms","volume":"26","author":"Wijnen","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1177\/0091270010370846-BIB2|cit2","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"key":"10.1177\/0091270010370846-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1172\/JCI116441","article-title":"Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans","volume":"91","author":"Evans","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1177\/0091270010370846-BIB4|cit4","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1177\/0091270010370846-BIB5|cit5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/00005344-198805000-00007","article-title":"Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist","volume":"11","author":"Water","year":"1988","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1177\/0091270010370846-BIB6|cit6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1524-6175.2007.06679.x","article-title":"A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension","volume":"9","author":"Weiss","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1177\/0091270010370846-BIB7|cit7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","article-title":"The efficacy and tolerability of nebivolol in hypertensive African American patients","volume":"9","author":"Saunders","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1177\/0091270010370846-BIB8|cit8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/hc3001.094207","article-title":"Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study","volume":"104","author":"Tzemos","year":"2001","journal-title":"Circulation"},{"key":"10.1177\/0091270010370846-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1345\/aph.1G708","article-title":"Nebivolol: a third-generation beta-adrenergic blocker","volume":"40","author":"Veverka","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1177\/0091270010370846-BIB10|cit10","unstructured":"Gu Z Robinson RA Cai L et al. Metabolism study of 14C-nebivolol in humans with different CYP2D6 genotypes 2003"},{"key":"10.1177\/0091270010370846-BIB11|cit11","unstructured":"Shaw AA Bland TM Tu HC et al. Single-dose, relative bioavailability and food effect study of nebivolol hydrochloride in healthy volunteers characterized according to their metabolizing status 2003"},{"key":"10.1177\/0091270010370846-BIB12|cit12","unstructured":"Shaw AA Bland TM Tu HC et al. Single-dose, dose-proportionality pharmacokinetic study of nebivolol hydrochloride in healthy volunteers characterized according to their metabolizing status 2003"},{"key":"10.1177\/0091270010370846-BIB13|cit13","doi-asserted-by":"crossref","first-page":"P77","DOI":"10.1016\/j.clpt.2004.12.184","article-title":"Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers [abstract PII-99]","volume":"77","author":"Shaw","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010370846-BIB14|cit14","unstructured":"Chien C Liang D Gu Z Robinson RA Wu J Huang M Mass balance study of 14C-nebivolol in humans with different CYP2D6 genotypes 2003"},{"issue":"suppl 1","key":"10.1177\/0091270010370846-BIB15|cit15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF03258259","article-title":"Clinical pharmacokinetics of nebivolol: a review","volume":"3","author":"Peer","year":"1991","journal-title":"Drug Invest"},{"key":"10.1177\/0091270010370846-BIB16|cit16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0091270007310378","article-title":"Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker","volume":"48","author":"Prisant","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1177\/0091270010370846-BIB17|cit17","doi-asserted-by":"crossref","first-page":"P38","DOI":"10.1016\/j.clpt.2004.12.037","article-title":"Effects of varying degrees of renal impairment on the pharmacokinetic disposition of nebivolol [abstract PI-115]","volume":"77","author":"Shaw","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010370846-BIB18|cit18","doi-asserted-by":"crossref","first-page":"P41","DOI":"10.1016\/j.clpt.2004.12.048","article-title":"Effects of hepatic impairment on the pharmacokinetic disposition of nebivolol: a dual acting nitric oxide modulating\/cardioselective beta1-antagonist [PI-126]","volume":"77","author":"Shaw","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010370846-BIB19|cit19","first-page":"2","article-title":"Experimental evidence of selective antagonistic action of nebivolol on beta-1-adrenergic receptors","volume":"2","author":"Cleophas","year":"1998","journal-title":"J Clin Med"},{"key":"10.1177\/0091270010370846-BIB20|cit20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s002280050217","article-title":"Pharmacological properties of nebivolol in man","volume":"51","author":"Bortel","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1177\/0091270010370846-BIB21|cit21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00005344-200305000-00014","article-title":"Effects of nebivolol on ischemia-induced metabolic changes in dog hearts","volume":"41","author":"Satoh","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1177\/0091270010370846-BIB22|cit22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/14656566.5.4.893","article-title":"Nebivolol: a review","volume":"5","author":"Cockcroft","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1177\/0091270010370846-BIB23|cit23","volume-title":"Bystolic [package insert]","year":"2007"},{"key":"10.1177\/0091270010370846-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1177\/0091270010370846-BIB25|cit25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0828-282X(06)70280-X","article-title":"The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension, part II: therapy","volume":"22","author":"Khan","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1177\/0091270010370846-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Expert consensus document on beta-adrenergic receptor blockers","volume":"25","author":"Lopez-Sendon","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1177\/0091270010370846-BIB27|cit27","volume-title":"Hypertension Management Guide for Doctors 2004","author":"National Blood Pressure Advisory Committee","year":"2004"},{"key":"10.1177\/0091270010370846-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension","volume":"21","author":"Whitworth","year":"2003","journal-title":"J Hypertens"},{"key":"10.1177\/0091270010370846-BIB29|cit29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.crd.0000223651.03023.8e","article-title":"Nebivolol: new therapy update","volume":"14","author":"Sule","year":"2006","journal-title":"Cardiol Rev"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010370846","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1177\/0091270010370846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:57:11Z","timestamp":1657803431000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010370846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010370846","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}